Article thumbnail

Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors

By Harold Bays and Peter H Jones


Colesevelam HCl is a bile acid sequestrant (BAS) which has been specifically designed with a unique structure for the purpose of improving tolerability and reducing potential drug interactions compared to older BAS, such as cholestyramine and colestipol. As a class, BAS are known to reduce cholesterol and glucose levels, and to reduce atherosclerotic coronary heart disease (CHD) risk as monotherapy, and in combination with other lipid-altering drug therapies. Colesevelam HCl has specifically been shown to reduce total and low-density lipoprotein (LDL) cholesterol levels, and has been approved as a cholesterol-lowering drug since year 2000. It has also been shown to reduce glucose levels. This discussion reviews mechanisms by which BAS lower cholesterol, and potential mechanisms by which BAS lower glucose levels in patients with type 2 diabetes mellitus. Finally this paper specifically reviews colesevelam HCl’s pharmacology, lipid and glucose efficacy, safety/tolerability, and clinical use

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). Abstract poster presentation. American Heart Association Annual Meeting,
  2. (2004). Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferatoractivated receptor gamma expression.
  3. (2003). Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue.
  4. (2006). Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.
  5. (2007). Addition of colesevelam HCl to patients with type 2 diabetes mellitus inadequately controlled on a metformin-based therapy improves glycemic control.
  6. (2006). Adiposopathy – defi ning, diagnosing, and establishing indications to treat “sick fat”: what are the regulatory considerations? US Endocrine Disease,
  7. (2006). Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr Atheroscler Rep,
  8. (2006). Adiposopathy: How do diet, exercise, weight loss and drug therapies improve metabolic disease? Expert Rev Cardiovasc Ther,
  9. (2005). Adiposopathy: Sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiology,
  10. (2006). Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidology,
  11. (2003). Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis.
  12. (1990). Benefi cial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
  13. (1987). Benefi cial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
  14. (2007). Cholesevelam hydrochloride. Accessed
  15. (2002). Cholesterol Education Program.
  16. (1994). Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial.
  17. (2006). Circulating intestinal fi broblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.
  18. (2007). Colesevelam HCl added to sulfonylurea-based therapy in patients with inadequately controlled type 2 diabetes mellitus improves glycemic control.
  19. (2006). Colesevelam HCl improves glycemic control in type 2 diabetes mellitus subjects managed with insulin therapy.
  20. (2003). Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother,
  21. (1998). Comparative dose effi cacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fl uvastatin in patients with hypercholesterolemia. the CURVES study.
  22. (2003). Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin. the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE].
  23. (2007). Dark green blood in the operating theatre.
  24. (2003). Dating of bruises in children: an assessment of physician accuracy.
  25. (2003). Defi nition of a novel growth factordependent signal cascade for the suppression of bile acid biosynthesis.
  26. (2006). Differences between clinical trial effi cacy and realworld effectiveness.
  27. (2006). Dove Medical Press Limited. All rights reserved REVIEW Leila Fernandes Araujo Alexandre de Matos Soeiro Juliano Lara Fernandes Antônio Eduardo Pesaro Carlos V Serrano
  28. (2006). Effective use of combination lipid therapy. Curr Atheroscler Rep,
  29. (2006). Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and highsensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
  30. (2006). Effects of colesevelam hydrochloride. WelChol. on biomarkers of infl ammation in patients with mild hypercholesterolemia.
  31. (1984). Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation,
  32. (1992). Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine,
  33. (2005). Effi cacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
  34. (2002). Effi cacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
  35. (2004). Extended-release niacin/lovastatin: the fi rst combination product for dyslipidemia. Expert Rev Cardiovasc Ther,
  36. (2006). Farnesoid X receptor is essential for normal glucose homeostasis.
  37. (2004). Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-defi cient diabetes.
  38. (2004). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
  39. (2006). Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin,
  40. (2004). Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells. Diabetes, 53(Suppl 3):S75–S8.
  41. (2003). Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol,
  42. (2002). Liver X receptors downregulate 11beta-hydroxysteroid dehydrogenase type 1 expression and activity.
  43. (2002). Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev Cell,
  44. (2002). LXR alpha is the dominant regulator of CYP7A1 transcription.
  45. (2004). Modulation of metabolic syndrome by fi broblast growth factor 19. FGF19? Endocrinology,
  46. (2003). Pharmacotherapy for dyslipidaemia – current therapies and future agents. Expert Opin Pharmacother,
  47. (2007). Rationale and design of a prospective clinical trial program to evaluate colesevelam’s glucose-lowering effects in patients with type 2 diabetes mellitus. Curr Med Res Opin,
  48. (2006). Rationale for intensive statin treatment in high-risk patients. Prev Cardiol,
  49. (1990). Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
  50. (1990). Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.
  51. (2005). Regulation of carbohydrate metabolism by the farnesoid X receptor.
  52. (2007). Results of the glucose-lowering effect of WelChol study. GLOWS: A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther,
  53. (2005). Results of the National Cholesterol Education. NCEP. Program Evaluation ProjecT Utilizing Novel E-Technology. NEPTUNE. II survey and implications for treatment under the recent NCEP Writing Group recommendations.
  54. (2000). Role of lipid-lowering pharmacotherapy in children. Paediatr Drugs,
  55. (2007). Roles of nuclear receptors in the up-regulation of hepatic cholesterol 7alpha-hydroxylase by cholestyramine in rats. Life Sci,
  56. (2005). Safety and effi cacy of colesevelam hydrochloride in combination with fenofi brate for the treatment of mixed hyperlipidemia.
  57. (2006). Statin safety: an overview and assessment of the data –
  58. (1999). The continuing importance of bile acids in liver and intestinal disease.
  59. (1984). The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.
  60. (1984). The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.
  61. (2007). The nuclear receptor LXR is a glucose sensor.
  62. (2002). The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. Mol Endocrinol,
  63. (2006). What are the long-term effects of statin therapy? Nat Clin Pract Cardiovasc Med,